Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is expected to be announcing its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $8.02 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Up 4.8 %

NASDAQ:TNGX opened at $1.95 on Friday. The stock has a market cap of $210.81 million, a P/E ratio of -1.65 and a beta of 0.87. The firm’s fifty day simple moving average is $2.63 and its 200 day simple moving average is $4.75. Tango Therapeutics has a twelve month low of $1.72 and a twelve month high of $12.02.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.33.

Insider Buying and Selling at Tango Therapeutics

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 24,268 shares of company stock valued at $72,561. 6.30% of the stock is currently owned by company insiders.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.